NCI sponsored, ECOG-ACRIN Phase 3 Study of Leukine in Combination with Ipilimumab and Nivolumab in Front Line Treatment of Melanoma Heads to Last Stages of Enrollment
/PRNewswire/ M2GEN, an oncology-focused health informatics solutions company, today announced its participation as a presenter, exhibitor, and research.
Patients with high-risk melanoma had better quality of life on pembrolizumab than on standard immunotherapy regimens miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.